Skip to main content

Advertisement

Table 2 CERTAIN patients who have been exposed to at least 1 TNF-α inhibitor (population used for primary comparative effectiveness analyses)

From: Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients

  All Anti-TNF agents initiators Non-anti-TNF agents initiators Standardized absolute mean difference
Total, n 1321 558 763  
Age (median, IQR), years 57 [47,65] 56 [47,64] 57 [48,66] 0.137
Female, n (%) 1037 (79.9) 434 (79.1) 603 (80.5) 0.036
Caucasian, n (%) 1091 (83.9) 446 (81.1) 645 (85.9) 0.129
RA disease duration (median, IQR), years 7 [3,14] 6 [3,12] 8 [4,15] 0.213
CDAI (median, IQR) 28 [21,38] 27 [20,38] 28 [21,38] 0.072
DAS28-CRP (median, IQR) 4.9 [4.2,5.6] 4.7 [4,5.4] 5.0 [4.3,5.7] 0.259
Biologic Monotherapy, n (%) 436 (33) 188 (33.7) 248 (32.5) 0.025
Concurrent DMARDs, n (%) 885 (67) 370 (66.3) 515 (67.5) 0.025
  MTX only, n (%) 586 (44.4) 258 (46.2) 328 (43) 0.065
  MTX dose (med, IQR) mg 20 [15,20] 20 [15,20] 20 [15,20] 0.018
  MTX plus other DMARDs, n (%) 95 (7.2) 40 (7.2) 55 (7.2) 0.002
  Leflunomide only, n (%) 78 (5.9) 28 (5) 50 (6.6) 0.066
  Sulfasalazine only, n (%) 18 (1.4) 4 (0.7) 14 (1.8) 0.100
  Hydroxychloroquine only, n (%) 53 (4) 20 (3.6) 33 (4.3) 0.038
Concomitant prednisone, n (%) 460 (34.8) 198 (35.5) 262 (34.3) 0.024
 Prednisone dose (median, IQR) mg/day 5 [5,10] 5 [5,10] 7 [5,10] 0.155
 No use, n (%) 877 (66.4) 363 (65.1) 514 (67.4) 0.049
 Prednisone <5 mg, n (%) 53 (4) 18 (3.2) 35 (4.6) 0.070
 Prednisone 5- <10 mg, n (%) 202 (15.3) 100 (17.9) 102 (13.4) 0.125
 Prednisone ≥ 10 mg, n (%) 189 (14.3) 77 (13.8) 112 (14.7) 0.025
Number of prior biologics exposed to (median, IQR) 1 [1,2] 1 [1,2] 1 [1,3] 0.427
Number of prior non-biologic DMARDs exposed to (median, IQR) 2 [1,3] 2 [1,2] 2 [1,3] 0.272
Biologic started at enrollment, n (%)     
 Adalimumab 122 (9.2) 122 (21.9) N/A N/A
 Infliximab 127 (9.6) 127 (22.8) N/A N/A
 Etanercept 101 (7.6) 101 (18.1) N/A N/A
 Golimumab 71 (5.4) 71 (12.7) N/A N/A
 Certolizumab 137 (10.4) 137 (24.6) N/A N/A
 Rituximab 125 (9.5) N/A 125 (16.4) N/A
 Abatacept 334 (25.3) N/A 334 (43.8) N/A
 Tocilizumab 304 (23) N/A 304 (39.8) N/A
Co-morbidities, n (%)     
 History of Cardiovascular disease* 104 (7.9) 42 (7.5) 62 (8.1) 0.022
 History of Hypertension 333 (31.9) 144 (33.6) 189 (30.7) 0.063
 History of Diabetes Mellitus 102 (10) 45 (10.8) 57 (9.5) 0.042
 Hyperlipidemia (Defined as: Total cholesterol > 240 mg/dL at baseline visit) 156 (13) 70 (13.6) 86 (12.5) 0.032
 History of Malignancy (includes non -melanoma skin cancers) 100 (7.6) 41 (7.3) 59 (7.7) 0.015
  1. Note: Standardized Absolute Mean Differences of 0.1 or less were considered clinically unimportant.
  2. Abbreviations: IQR interquartile range, MTX methotrexate, CDAI clinical disease activity index, DAS28_CRP disease activity score with 28 joint counts and CRP (C– reactive protein) as the inflammatory marker.
  3. *History of cardiovascular disease included: cardiac revascularization procedures, ventricular arrhythmias, cardiac arrests, myocardial infarctions, acute coronary syndromes, unstable angina, coronary artery disease, congestive heart failure, stroke, transient ischemic attacks.
  4. (Data for patients enrolled as of October 7th 2013).